Cross-posted from the TARGET CenterExit Disclaimer

Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair

The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and in journal articles. Headlines follow, and care providers in thousands of clinics and offices around the world figure out what this new knowledge means for their practice and their patients. The annual Ryan White HIV/AIDS Program Clinical Care ConferenceExit Disclaimer serves as a venue where these providers can discuss these developments with their peers and expert clinicians. 

“It’s a great balance between state-of-the-art treatment and science and pragmatic things that Ryan White HIV/AIDS Program providers struggle with and need assistance with,” said Dr. Laura Cheever, Associate Administrator of the HRSA HIV/AIDS Bureau, which oversees the federal Ryan White HIV/AIDS Program (RWHAP). Cheever said this learning format is particularly helpful to grant recipients such as RWHAP Part C clinics, in order to “meet the educational needs of these expert clinicians.”

“We are coming to a new era of ARVs [antiretrovirals] that will probably change our patterns of prescribing. One advancement under study is long acting agents, including two by injection. They may be coming soon, in the next few years, for both treatment and PrEP.” Dr. Laura Cheever

The 17th RWHAP Clinical Conference was held in San Antonio on August 21-23. In addition to the more than 300 attendees, clinicians across the country could participate via live stream or access online archives for web viewing. We touched base with Dr. Cheever, one of the co-chairs of the conference, to get some highlights.

For more information on this post, visit the TARGET CenterExit Disclaimer.